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Lung cancer: overview of incidence, risk factors, treatment and survival 
In the last century lung cancer incidence has progressively increased, becoming the most 
common diagnosed cancer (GLOBOCAN 2018 estimates: 11.6% of 18.1 million new cancer 
cases) and the leading cause of cancer-related death (GLOBOCAN 2018 estimates: 18.4% of 
9.6 million cancer-related deaths), worldwide [1-3]. 
Focusing on our country, the estimated new cases of lung cancer in Italy in 2018 are 27,900 for 
men and 13,600 for women, for a total of 41,500 (11% of 373,300 new cancer cases) [4]. Thus, 
lung cancer is the third most commune cancer in Italy after colorectal (14%) and breast cancer 
(14%) [4]. 
 
Lung cancer rarely involves men and women <50 years old. If fact, concentrating on Italian 
data, only 5% and 2% of all cancer are represented by lung tumor respectively among men and 
women before their 50s [4]. Conversely, lung cancer is the 2nd most common cancer among 
men between 50-69 years old (14% of all cancers) and >70 years old (17% of all cancers) after 
bladder cancer [4]. Likewise, it is the 3rd most common cancer among women between 50-69 
years old (7% of all cancers) and >70 years old (7% of all cancers) after breast and colorectal 
cancer [4]. Interestingly, the incidence of lung cancer among women has been continuously 
rising since the mid 1970s, leading its total annual incidence to increase of +1.7% between 2006 
and 2014 [5]. This impressive rise is due to a simultaneous increase of female smokers’ number 
which has reached 5.7 million (19.2% of all women) in 2018 [4]. 
 
As known, cigarette smoking is the main risk factor for lung cancer, with 85-90% of all lung 
tumors attributable to this habit [1-3,5]. Lung cancer risk increases with number of cigarettes 
smoked per day and smoking duration. In fact, it is about 14 times higher in smokers than never 
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smokers and more than 20 times higher in heavy smokers (people smoking >20 cigarettes per 
day) [1-3,5]. 
Other factors associated with increased lung cancer risk include ionizing radiation, 
environmental toxins, such as secondhand smoke, radon, metals (arsenic, chromium, and 
nickel) and polycyclic aromatic hydrocarbons [1-3,5-8]. Moreover, also history of pulmonary 
fibrosis, human immunodeficiency virus infection, and alcohol consumption have been defined 
as risk factors for lung cancer [1-3,5-8]. 
 
Regarding mortality, lung cancer is the leading cause of cancer-related death worldwide [1-3]. 
In detail, in Italy, it is the first cause of death for cancer among men (26% of all cancer deaths) 
and the 3rd cause of cancer-related death among women (11% of all cancer deaths) [5]. It has 
been estimated that 1 every 11 men and 1 every 46 women are at risk of dying for lung cancer 
during their life, with an overall of 33,836 deaths for lung cancer recorded in Italy in 2015 [5]. 
Unfortunately, the most of lung cancer cases (>50%) are detected in advanced stage, with few 
treatment options available and with a consequently poor survival (advanced lung cancer 5-
year survival: 5%), despite significant advances continue to be made and treatment has become 
nuanced and specific for particular histologic subtypes, clinical patient characteristics and 
presence of specific genetic mutations [5-9]. This explain why lung cancer has one of the lowest 
survivals, with 5-year relative survival rate for all stages combined of 15.8% [5]. 
 
This suggest the importance of diagnosing lung cancer in early stage, when it is still 
asymptomatic and it hasn’t yet spread to mediastinal lymph nodes and/or distant organs, in 
order to treat and cure it, improving patients’ prognosis. To date, radical surgery is still the 
treatment of choice for lung cancer. In depth, there are two main forms of lung cancer: non-
small cell lung cancer (NSCLC) (85% of all lung cancer patients) and small cell lung cancer 
(15% of all lung cancer patients). Small cell lung cancer, with its high proliferation rate, is 
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highly aggressive and most of patients already have distant occult metastases at time of 
presentation with surgery indicated only in selected cases and always as part of a multimodal 
therapy which combines surgery, chemotherapy and radiotherapy [10]. Conversely, surgery is 
the “gold standard” treatment for potentially resectable NSCLC. In detail, if at preoperative 
evaluation, no distant metastases has been detected and no mediastinal lymph nodes are 
involved by tumor (clinical stage I or II) or if tumor has already metastasized only to one 
ipsilateral mediastinal lymph node station (clinical stage IIIA “single station”) tumor surgical 
resection is suggested as first treatment approach (NSCLC 8th edition TNM Staging System is 
explained at pages 38-40) [11,12,13]. Overall 5-year survival rate of NSCLC patients 
undergoing tumor surgical resection is more reassuring than that one of patients not fit for 
surgery, and is 80-90% for pathological stage IA disease, 73% for stage IB, 65% for stage IIA 
and 56% for stage IIB, with a worse prognosis for poorly differentiated tumor, tumor with size 
>4 cm, presence of pleura infiltration and/or neuro-vascular invasion [11,13]. 
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Non-small cell lung cancer surgery: indications, surgical procedures and 
postoperative outcomes 
After stating tumor surgical resection as the cornerstone of non-small cell lung cancer (NSCLC) 
treatment, we move our attention on principles of lung cancer surgery. 
First, surgery should be considered only for potentially resectable NSCLC (clinical stage I-II 
disease and clinical stage IIIA disease only in selected cases), and it should be realized with the 
purpose of obtaining a R0 (no residual tumor) resection. 
Thus, an accurate preoperative tumor staging by chest computed tomography scan, 18F-
fluorodeoxyglucose positron emission tomography and brain computed tomography 
scan/magnetic resonance imaging is fundamental to assess the presence of lymph nodes and 
distant metastases (liver, adrenal glands, bones and brain) before surgery. 
Whenever mediastinal lymph nodes are >1 cm in size at computed tomography scan and/or 
have positive uptake at 18F-fluorodeoxyglucose positron emission tomography and/or  primary 
tumor is closed to lung hilar structures and/or it is >3 cm in size and/or hilar/intraparenchymal 
lymph nodes are suspicious for metastases, mediastinal lymph nodes assessment by 
endobronchial ultrasound-transbronchial needle aspiration or video-assisted mediastinoscopy 
is required [11,12,14]. 
If no distant metastases are detected and no mediastinal lymph nodes are involved by tumor 
(clinical stage I or II) or if tumor has already spread, but only to an unique ipsilateral mediastinal 
lymph node station (clinical stage IIIA “single station”), tumor surgical resection and hilar-
mediastinal lymph nodes dissection is suggested as the first step in NSCLC treatment process 
[11,12]. 
 
After assessing tumor histology (small cell versus non-small cell) and extension (stage), it is 
mandatory to evaluate patient age, comorbidity and respiratory function in order to determine 
whether an individual patient is able to cope with reduced pulmonary and vascular reserve 
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capacity after surgical resection and to maintain an acceptable quality of life. For those patients 
who are not willing to accept surgery-related risks, or are at high risk for surgery, alternative 
local therapy as curative radiotherapy (either stereotactic ablative body radiation therapy or 
hypofractionated high-dose radiotherapy) or radiofrequency/microwave ablation should be 
offered [11,12]. 
 
Regarding surgical procedure itself, lung lobectomy (surgical resection of a single lung lobe) 
with hilar-mediastinal lymphadenectomy is still considered the standard surgical treatment of 
NSCLC [12]. 
However, two phase III randomized trial (CALGB 140503 and JCOG0802/WJOG4607L) 
comparing lung lobectomy to lung sublobar resection [either segmentectomy (surgical resection 
of a lung segment) or wedge resection (non-anatomical sublobar lung resection)] for NSCLC 
<2 cm are still ongoing and in the next years they are disclosing if lung sublobar resection is 
comparable to lung lobectomy in terms of disease-free survival, overall survival, patterns of 
tumor recurrence and postoperative pulmonary function, maybe changing surgical approach to 
NSCLC <2cm [14-16]. 
 
Concerning hilar-mediastinal lymphadenectomy, it is admitted that nodal staging of NSCLC 
should be as accurate as possible and intraoperative mediastinal lymph node assessment is 
mandatory to improve nodal staging itself and patients’ survival. Though, the extent of 
mediastinal lymphadenectomy is still controversial and different techniques ranging from 
mediastinal lymph node sampling to systematic lymph node dissection could be employed. 
Sampling is the removal of one or more lymph nodes guided by preoperative or intraoperative 
findings which are thought to be representative. Systematic sampling means a predetermined 
selection of the lymph node stations specified by surgeon. Systematic nodes dissection consists 
in dissecting and removing all the mediastinal tissue containing lymph nodes systematically 
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within anatomical landmarks. Finally, lobe-specific systematic nodes dissection is defined as 
the excision of mediastinal tissue containing specific lymph node stations depending on lobar 
location of primary tumor (i.e. in right upper lobe NSCLC cases, a part of subcarinal nodal 
station, upper and lower right paratracheal nodal stations should be dissected and removed) 
[17]. 
Since the management of lymph nodes during surgery is mainly dictated by the staging 
requirements for guaranteed “R0 resection” status, it is recommended that at least six 
nodes/stations, three of which should be mediastinal nodal stations (but always subcarinal 
station) should be excised as a minimum requirement [12,18,19]. 
While in stage I NSCLC overall survival, loco-regional and systemic recurrence rate are not 
influenced by intraoperative mediastinal lymph node assessment technique, systematic nodal 
dissection is recommended in stages II and IIIA despite it has been demonstrated that complete 
mediastinal lymphadenectomy adds little morbidity to pulmonary resection for lung cancer [12 
,20,21]. 
 
Whether surgery should be performed through standard open thoracotomy or video-assisted 
thoracoscopic surgery (VATS) procedure, is probably less significant from oncological 
perspective, since comparative margin clearance and nodal dissection can be achieved [12 ,22]. 
However, the introduction of VATS has led to reduction of postoperative morbidity, length of 
stay and, in some studies, of mortality when compared to open thoracotomy, probably as a 
consequence of tissue injury and stress response minimization due to the mini-invasive 
approach [23-25]. These promising results have allowed a rapid diffusion of this technique that 
is widely preferred to thoracotomy almost in all experienced centers. 
 
Despite VATS improvement of patients’ postoperative outcomes, mortality and morbidity at 
30 days after VATS lobectomy for NSCLC are not negligible, ranging between 0-2.7% and 6-
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36.6%, respectively [26-28]. The most frequent postoperative complications are atrial 
fibrillation (2.9-12%), persistent air leak (15-18%) pneumonia (6%), hemothorax (2.9%), 
chylothorax (0.7-2%) middle lobe torsion (0.09-0.4%), phrenic and recurrent laryngeal nerve 
injury (<1%) [26-29]. 
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Video-assisted thoracoscopic surgery lobectomy and lymphadenectomy 
technique 
Despite video-assisted thoracoscopic surgery (VATS) lobectomy and lymphadenectomy can be 
performed using up to five incisions, the fundamental steps to realize this procedure are similar 
even using different ports number and different approach (anterior\posterior). 
 
In all anterior approaches, the camera port (5 to 10 mm) is typically placed low in the chest (7th 
or 8th intercostal space), either in the mid or anterior axillary line and 30 degrees camera is used 
to have a complete view of the surgical field [30-33]. A “utility” incision (3 to 6 cm) is usually 
placed anterior to latissimus dorsi muscle, over the anterior hilum and the major pulmonary 
vessels (4th or 5th intercostal space). A soft tissue retractor is often used at this incision to protect 
surrounding tissue [30-33]. Third, fourth and fifth incisions (10 mm) are placed either high in 
the mid-axillary line, or low in the chest in the posterior axillary line. In all cases, no rib 
spreading is used at any of incision sites and only monitor based vision is allowed (Figure 1) 
[30-33]. 
In case of uniportal VATS, a unique incision (3-6 cm) is performed anterior to latissimus dorsi 
muscle at 5th intercostal space. A soft tissue retractor is used at this incision where camera is 
placed at the top and the other instruments at the bottom [34-35]. 
For the posterior approach “utility” incision is made anterior to latissimus dorsi muscle at 6th 
or 7th intercostal space instead of 4th intercostal space and the camera port is made through the 
auscultatory triangle, instead of lower anterior incision [36]. 
 
Tissue dissection starts at lung hilum where mediastinal pleura is incised over the anterior and 
posterior aspect of the hilum to provide anatomic structure exposure. During this procedure 
vital structures such as phrenic and recurrent laryngeal nerves should be identified early and 
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preserved [30,33,34,36]. Tissue dissection is performed by dissectors, forceps, graspers, 
suckers, scissors, “sponge-sticks” and energy devices (Figure 2-3). 
Pulmonary vessels (veins and arteries) and bronchi within the hilum are ligated with endoscopic 
staplers. Alternatively, small vessels (5-7 mm) can be clipped and dissected or coagulated and 
transected by energy devices [30,33,34,36]. 
Fissures are usually stapled unless complete, in which case cautery may be used. In order to 
better manage incomplete fissure and to minimize the risk of prolonged postoperative air leak, 
surgeons prefer to perform the “fissure-less technique”. This technique consists in a progressive 
dissection of hilar structures and in stapling the involved fissure last with the visceral pleura 
intact as a seal above the parenchyma, giving a tighter closure within the stapling line, and no 
scars in the tissue next to the clips [30,33,34,36]. 
Specimen is removed using a specimen bag, to minimize contact with soft tissues at the “utility” 
incision site and to consequently reduce incidence of “port-site” recurrence. 
 
Removal of hilar and lobar lymph nodes is performed during hilar structures ligation (Figure 
4). For mediastinal lymph nodes, in right-sided procedures, the pleura is opened above and 
under the azygos vein. Right upper and lower paratracheal lymph nodal stations “en-bloc” 
dissection begins at the tracheobronchial angle and progresses upwards under the azygos vein 
in order to clean off all the fatty tissue of the superior mediastinum [30,33,34,36]. 
On the left side, lymph nodes are removed “en-bloc” from subaortic and paraaortic stations, 
excising the greasy tissue between the aorta and the main pulmonary artery, after recurrent 
laryngeal nerve identification. 
In both right and left sides, subcarinal lymph nodes are approached after dividing the inferior 
ligament and opening the pleura on the posterior limit of the lung up to the carina. In this way 
subcarinal nodes are exposed and all the fatty tissue at this level is removed so that carinal 
bifurcation and opposite bronchus are clearly visible [30,33,34,36]. Finally, paraesophageal and 
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pulmonary ligament lymph nodes are removed during pulmonary ligament division and hilar 
structure dissection. 
 
At the end f the surgical procedure, one intercostal drain is placed in through the camera incision 
or through “utility” incision if uniportal VATS is performed. The drainage is left in place till 
there is no air-leak and less than <5 mL/kg of fluid after 24 hours according to the last Italian 
enhanced recovery after surgery guidelines [37]. 
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Figure 1 Three-port video-assisted thoracoscopic lobectomy and lymphadenectomy [33] 
 
 
The 5 cm “utility” incision anterior to latissimus dorsi muscle at 4th-5th intercostal space and 
the other two incision at the bottom (the anterior one is the camera port). 
 
 
Figure 2 The use of electric hook (monopolar device) in adhesiolysis (a) and hilar structure 
dissection (b). 
 
L=lung lobe; P=pericardium; PH=phrenic nerve; PV=pulmonary vein. 
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Figure 3 The use of the Harmonic ACE Plus® (ultrasonic device) in hilar structure dissection. 
 
B=right upper lobe bronchus; L=lung lobe; PA=pulmonary artery. 
 
 
Figure 4 Interlobar lymph nodes dissection by electric hook (monopolar energy device) (a) and 
by Harmonic ACE Plus® (ultrasonic device) (b). 
 
L=lung lobe; LY=lymph node; PA=pulmonary artery. 
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Energy devices in video-assisted thoracoscopic lobectomy and 
lymphadenectomy: monopolar and ultrasonic instruments 
Since the first electrosurgical unit was created by Dr William T. Bovie and Dr Harvey W. 
Cushing in 1920, there have been important improvements in energy device field and several 
different instruments have been introduced in thoracic surgeons’ daily practice in order to cut, 
dissect tissue and seal vessels [38]. However, most surgeons are still not familiar with the 
technology behind them, or their applications [39,40]. 
 
During video-assisted thoracoscopic (VATS) lung lobectomy and lymphadenectomy, energy 
devices are employed with different purposes: division of pleural adhesions, hilar structures 
dissection, small vessels coagulation and transection and lymph nodes dissection and removal. 
Several devices with different technology have been using during this surgical procedure. In 
this session we are focusing only on the electric hook (Figure 4) and the Harmonic ACE Plus® 
(Figure 5) (Johnson & Johnson Medical). 
 
The electric hook (Figure 4) is a monopolar energy device and it directly uses high-frequency 
electric current to cut tissue and coagulate vessels [41]. The electric current flows from the 
generator to the active electrode (the device itself) and, passing through the patient, concludes 
the electric circuit reaching the dispersive cautery pad [40]. In detail, heat production by electric 
current concentration in a small tissue area (the area touched by the instrument itself) leads to 
tissue thermal damage and to the majority of the tissue effects in electrosurgery: coagulation 
occurs when tissue is heated below the boiling point and undergoes thermal denaturation; 
desiccation when a slow temperature increase leads to vaporization of tissue water; 
fragmentation and cutting when a sudden increase in tissue temperature above the boiling point 
causes rapid explosive vaporization of tissue water [41]. Thus, electrocautery can be used for 
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tissue dissection, but alone it is inefficient and potentially inappropriate for larger (>3 mm) 
parenchymal blood vessels sealing and division. 
 
One of the recent advancements in surgical devices for cutting and coagulating tissue has been 
the introduction of the Harmonic ACE Plus® (Johnson & Johnson Medical) (Figure 5): an 
ultrasonic surgical instrument for cutting and coagulating tissue, operating at a frequency of 
55.5 kHz oscillations per second. There is no electrosurgical current generated. The 
combination of mechanical energy due to its blade tip oscillations and the heat that is generated 
causes protein denaturation and formation of a coagulum that seals blood vessels up to 5 mm 
in diameter and up to 7 mm in the new device version Harmonic ACE®+7 [42-45]. Moreover, 
the blade tip vibrations produce large transient pressure changes, which causes cellular low 
temperature water vaporization with consequently cells rupture, and tissue stretching with 
molecular bands separation, leading to an accurate cutting and dissection. 
 
With their different technology, electric hook and Harmonic ACE Plus® have a different impact 
on target tissue but mainly on surrounding structures [46-50]. In evaluating energy device 
performance to test the lateral thermal spread is fundamental because it is a measurement of the 
device potential damage to surrounding sensitive structures including vessels and nerves [48-
50]. The degree of lateral thermal spread varied by instrument type, power setting and 
application time. Recent studies have showed that monopolar instruments result in a greater 
degree of thermal damage when compared to ultrasonic devices which has a lateral thermal 
damage of about 3 mm [48-50]. However, this difference does not imply a higher risk of 
intraoperative complication due to energy device itself, suggesting that surgeon’s awareness 
about instruments technology and application within the use of protected-tip cautery may 
balance these devices different effects [46-47]. 
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In the literature, some study has been published with the aim of evaluating vessel sealing 
technology devices efficacy but no study focuses on comparing Harmonic ACE Plus® to the 
more commune electrosurgical devices, in terms of postoperative blood\lymph leaks, 
postoperative morbidity and postoperative length of stay after VATS pulmonary lobectomy and 
lymph node dissection for non-small cell lung cancer has been reported yet [42,51-55]. A 
similar study comparing bipolar to monopolar devices in VATS pulmonary lobectomy and 
















This study aims to assess and compare surgical electric hook vs Harmonic ACE Plus® impact 
on short-term postoperative outcomes after video-assisted thoracoscopic surgery pulmonary 
lobectomy and lymph node dissection for non-small cell lung cancer. 
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Materials and methods 
We prospectively collected data of consecutive patients who underwent lung lobectomy and 
lymphadenectomy in our Center from October 1st 2016 to July 31th 2019. We excluded patients 
undergoing surgery for benign disease or for lung metastases; those requiring conversion from 
video-assisted thoracoscopic surgery (VATS) to thoracotomy or approached by thoracotomy; 
those undergoing extended resection to chest wall, mediastinum and another lung lobe and 
those requiring the use of more than one dissecting devices. 
This study was approved by our Center Ethic Committee and individual patient consent was 
obtained for each patient. 
 
All lung lobectomies and lymph node dissections were performed using the standardized three-
port anterior approach [33]. All the procedures were performed by experienced surgeons who 
had already completed the learning curve for VATS lobectomy and lymphadenectomy. A chest 
tube of 28 French in size was left in place after surgery until no air-leak was observed and 
secretion quantities was <250 ml/day. During the postoperative stay all patients were managed 
according to our Center standardized protocol which provides: perioperative respiratory 
physiotherapy; epidural analgesia/paravertebral block in association with non-steroidal 
analgesic painkillers for pain control; antithrombotic prophylaxis; intravenous fluid restriction; 
early oral feeding (on the day of surgery or postoperative day 1); early urinary catheter removal 
(on postoperative day 1), early ambulation (on postoperative day one).  
 
For each patient we collected the following records: age, gender, body mass index (BMI), 
smoking habit, comorbidities, forced expiratory volume in 1 second (FEV1), diffusion capacity 
for carbon monoxide (DLCO), surgical procedure, surgery duration, tumor histology and size, 
number of dissected lymph nodes, tumor pathological stage according to the 8th edition TNM 
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staging system, pleural effusion volume during the first 48 postoperative hours, postoperative 
chest tube stay, postoperative length of stay and 30-day postoperative complications. 
 
Patients were divided in two groups based on the device used for tissue dissection during 
surgery: the electric hook (Group A) or the Harmonic ACE Plus® (Group B). All surgical 
procedures were performed by experienced surgeons. The use of electric hook or Harmonic 
ACE Plus® was left to devices availability and to surgeon preference. 
 
Patients’ clinical and pathological characteristics were compared between Group A and Group 
B. 
 
The benchmarks used to evaluate and compare the impact of electric hook to the one of 
Harmonic ACE Plus® on postoperative course were postoperative hemo/chylothorax 
incidence, pleural effusion volume during the first 48 postoperative hours and postoperative 
chest tube duration. 
 
Univariable and multivariable analyses were performed in order to test energy device as 
possible independent risk factor for pleural effusion volume during the first 48 postoperative 
hours and for postoperative chest tube duration. Factors analyzed were age, gender, BMI, 
cardiac comorbidities, FEV1, DLCO, pleural adhesiolysis, number of resected lymph nodes, 
energy device (Harmonic ACE Plus® versus electric hook), site of resection (upper/middle lobe 
lobectomy vs lower lobe lobectomy), surgery duration, postoperative persistent air-leak (>5 
days after surgery). 
 
Continuous data were reported as median with interquartile range (IQR) and compared using 
T-test for normally distributed data and Mann–Whitney U test for non-normally distributed 
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data. Categorical and count data were presented as frequencies and percentages and compared 
using Chi-square test or Fisher’s exact test if any expected frequency was less than 5.  
Univariable and multivariable analyses were performed by binary logistic regression, using as 
cut-off value of dependent variable its median value. Significant factors at univariable analyses 
were included in multivariable analyses. A p-value <0.05 was considered significant. Statistical 




During the study period, 184 patients underwent lung lobectomy in our Center. According to 
study exclusion criteria, 64 patients were excluded from the study for the following reasons: 43 
patients were approached by thoracotomy, 10 patients underwent surgery for benign disease or 
for lung metastases, 6 patients required conversion from video-assisted thoracoscopic surgery 
(VATS) to thoracotomy (2 intraoperative bleeding, 2 locally advanced disease and 1 lung 
failure to collapse) and in 5 cases surgeon used both devices. Thus, 120 patients were left for 
statistical analysis.  
 
All patients underwent VATS lung lobectomy and lymphadenectomy for non-small cell lung 
cancer. Tissue and lymph nodes dissection were performed by electric hook in 68 cases (Group 
A) and by Harmonic ACE Plus® in 52 cases (Group B). 
Group A and B patients’ clinical characteristics are listed in Table 1. No patients reported 
coagulopathy, liver cirrhosis or renal failure in their past medical history in both groups. No 
difference in terms of clinical data were detected between the two groups (Table 1).  
 
Pleural adhesiolysis was required in 40 (33%) cases: 21 (31%) in Group A and in 19 (37%) in 
Group B (p-value=0.51). Surgery involved the right upper lobe in 38/120 patients (32%), 
middle lobe in 9 (7%), right lower lobe in 25 (21%), left upper lobe in 28 (23%) and left lower 
lobe in 20 (17%). Tumor lobe distribution was significantly different between Group A and 
Group B (p-value<0.01) with a lower rate of lower lobectomies in Group A (25% vs 54% Group 
B) (Table 2). A median of 3 (IQR: 3-4) N1 and N2 lymph node stations were dissected during 
surgery, with no difference in terms of overall number of lymph node excised between the two 
groups [Group A vs Group B: 8 (6-10) vs 8 (5-12); p-value=0.44]. Overall surgery duration 
was 195 minutes (IQR: 170-235). Surgical procedure lasted more time in Group B than in 
Group A: 214 (IQR: 190-261) vs 180 (IQR: 164-211) minutes, respectively (p-value<0.01). 
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Overall intraoperative leak was >100 ml in 29 (27%) patients with no differences between 
Group A and Group B [15 (23%) vs 14 (33%) patients respectively; p-value=0.26]. This data 
was not reported in 11 cases. No intraoperative complications due to energy device use were 
recorded in both groups. 
 
Final pathological results are reported in Table 2. Group A and Group B tumor size, histology 
and pathological stage distribution were comparable (Table 2). 
 
Overall 30-day mortality was 0.8% (1/120): 1 patient of Group A died of pulmonary embolism. 
However, no significant difference in term of 30-day mortality was detected between the two 
groups (1.5% vs 0%; p-value=1.00). 
Overall 30-day morbidity was 31% (37/120). During postoperative stay 24/120 (20%) patients 
developed persistent air leak (>5 days), 8 (7%) pneumonia, 3 (3%) atrial fibrillation, 2 (2%) 
chylothorax. No postoperative hemothorax was reported. Chylothorax incidence was higher in 
Group A than Group B, with no statistically significant difference between the two groups (3% 
vs 0%, respectively; p-value=0.50). 
Pleural effusion volume during the first 48 postoperative hours was significantly higher in 
Group B than in Group A: 253 ml (IQR: 149-405) vs 408 (IQR: 294-508) ml respectively; p-
value<0.01. However, chest tube duration was similar in Group A and Group B: 4 (IQR: 3-8) 
days vs 5 (IQR: 4-8) days; p-value=0.39. Likewise, there was no difference in terms of 
postoperative length of stay between the two groups: 7 (IQR: 5-9) days vs 7 (IQR: 6-9) days; 
p-value=0.65. 
 
At multivariable analysis energy device was not independently associated with pleural effusion 
volume during the first 48 postoperative hours and with postoperative chest tube duration 
(Table 3-4).  
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Discussion 
The use of energy devices during surgical procedure has been increasing since their invention 
in 1920 [38]. To date several energy tools, some of which have similar applications but different 
technologies, have been introduced in different surgical fields. In thoracic surgery and 
particularly in video-assisted thoracoscopic (VATS) lobectomy and lymph nodes dissection, 
energy devices are employed during almost all the surgical procedure for adhesiolysis, hilar 
structures dissection, small vessels sealing and finally for lymph nodes removal. 
Different energy tools can be used during this surgical procedure (i.e. electric hook, Harmonic 
ACE Plus®, LigaSureTM, Enseal®). However, no studies have compared the performance of 
different energy devices in terms of short-term outcomes after VATS lobectomy and 
lymphadenectomy and only few studies have evaluated and compared their efficacy in sealing 
pulmonary vessels, in non-human and human models [42-45]. 
In this study we’ve compared the impact of electric hook (monopolar device) to Harmonic ACE 
Plus® (ultrasonic device) on short-term outcomes after VATS lobectomy and 
lymphadenectomy for non-small cell lung cancer. 
The use of either electric hook or Harmonic ACE Plus® during adhesiolysis, hilar structure 
dissection and lymph nodes dissection is safe, with no intraoperative complications related to 
the use of one or the other energy device reported. During the postoperative stay, despite the 
significant pleural effusion volume increase during the first 48 postoperative hours after using 
Harmonic ACE Plus®, no statistically significant difference in terms of chylothorax incidence, 
chest tube duration and length of stay has been detected between electric hook and Harmonic 
ACE Plus®. Moreover, energy device was not recognized as an independent risk factor of either 
increased pleural effusion volume during the first 48 postoperative hours or prolonged 
postoperative chest tube duration. 
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In this study no intraoperative complications due to energy device have been recorded. This 
supports literature data which estimates that surgical energy injuries occur only in 1-2 per 1,000 
operations (0.1-0.2%) [46]. Energy devices complications are generally due to four main 
causes: thermal burn, hemorrhage, mechanical failure, and fire. Thermal burn, that is the result 
of direct application, dispersive electrode burns or insulation failure, is the most common reason 
for both injury and death and it has an incidence of 3% in thoracic surgery [47]. In our study 
no intraoperative injuries due to thermal burn has occurred despite the well-known higher 
lateral thermal spread of monopolar than ultrasonic device [48-50]. This suggests that surgeon 
awareness of energy device application, technology and common injury patterns within the use 
of protected-tip cautery is essential to minimize complications due to these instruments. 
 
No statistically significant differences were detected also in postoperative chylothorax and 
hemothorax incidence after using monopolar and ultrasound device. However, chylothorax rate 
was slightly higher after using electric hook than Harmonic ACE Plus® (3% vs 0%, 
respectively; p-value=0.50). This difference, despite not statistically significant, could be 
explained by devices application. Electric hook has been created with the aim of cutting and 
coagulating tissue, sealing vassels <3 mm, while Harmonic ACE Plus® has been created with 
the purpose of providing a strong and secure sealing in vessels up to 5 mm in diameter and up 
to 7 mm with its last version (Harmonic ACE®+7) [48,50,51]. This different performance could 
justify electric hook higher incidence of postoperative lymph leaks. 
 
Conversely, a significantly higher pleural effusion volume during the first 48 postoperative 
hours was detected after using the ultrasonic tool. However, multivariable analysis identified 
lower lung lobectomies, increased surgery duration and cardiac comorbidities but not energy 
device as risk factors for increased fluid leak during 48 hours after surgery. This suggests that 
the higher pleural effusion volume detected during the first 48 postoperative hours after using 
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Harmonic ACE Plus® may be due to the higher rate of lower lung lobectomies and the 
prolonged surgery duration reported in the ultrasonic device group. 
 
Additionally, chest tube duration was similar after using electric hook and Harmonic ACE 
Plus®, even when the two groups has been adjusted for other possible risk factors for prolonged 
postoperative chest tube stay at multivariable analysis. This suggests that, beside the two cases 
of chylothorax in monopolar device group, higher pleural effusion volume during the first 48 
postoperative hours in Harmonic ACE Plus® group and devices slightly different purposes, 
both instruments have a comparable performance in controlling postoperative fluid production, 
that is generally due to both pleural irritation and hilar structures-lymph nodes dissection. 
The similar chest tube duration resulted in an absence of difference in terms of postoperative 
length of stay between the two devices groups because, besides postoperative complications, 
the main factor driving discharge is chest tube length of stay. 
 
The only difference we observed in the usage of monopolar and ultrasonic devices was surgery 
duration: surgery lasted longer in Harmonic ACE Plus® group. We try to explain this difference 
taking into consideration instruments and surgical procedure characteristics. Harmonic ACE 
Plus® with its curved tip and its ergonomic shape is easy to use, and surgeons in our and other 
Institutions has been using it from several years and in different fields without reporting any 
complains. This suggests that this surgery prolongation in time is not due to the device itself 
but probably to surgical procedure complexity. In fact, in the Harmonic ACE Plus® group a 
significantly higher rate of lower lung lobectomies, that could be more challenging that middle 
and upper lobe lobectomies, has been performed (54% versus 25% of the electric hook). 
 
Finally, in terms of cost-effectiveness, Harmonic ACE Plus® with its innovative technology is 
more expensive than electric hook that is reusable: its prize is fourfold in our Institution. So, in 
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absence of Harmonic ACE Plus® positive impact in postoperative short-term outcomes, the 
use of electric hook may be useful in reducing operative costs. However, the safe use of the 
ultrasonic devices even in pulmonary vein and artery branches sealing could decrease the use 
of endoscopic staplers and ligating clips maybe reducing the overall operative costs which is 
mostly due the use of disposable equipment/devices [45,48,50-53]. In our study no data about 
the number of endoscopic staplers and charges saved in the Harmonic ACE Plus® group are 
available because no surgeons used the ultrasonic device to seal pulmonary vein and artery 
branches. 
 
This study has some limits. The use of electric hook or Harmonic ACE Plus® was not dictated 
by a randomized process but by devices availability and surgeon’s preference. However, 
patients had similar characteristics in both groups and a propensity score matching analysis was 
performed adjusting groups for those two factors which could have influenced study outcomes 
measurements: number of lymph nodes dissected and presence of postoperative air-leak. 
Secondly, no data have been reported about Harmonic ACE Plus® performance in sealing small 
vessels up to 5 mm because surgeons preferred to employ endoscopic staplers or clips. Finally, 
we did not report data about patients’ intraoperative and postoperative cost. However, we 
evaluated indirect indicators of overall cost as devices cost, length of surgery, postoperative 
complications, postoperative length of stay. A strength of this study is its aim: the evaluation 
of electric hook and Harmonic ACE Plus® impact on patients’ postoperative course. 
 
To conclude, the use of either surgical electric hook (monopolar device) or Harmonic ACE 
Plus® (ultrasonic device) for adhesiolysis, hilar structure dissection and lymph nodes dissection 
in VATS lobectomy and lymphadenectomy is safe and these two devices are associated with 
similar postoperative chylothorax incidence, chest tube duration and length of stay. Further 
randomized and larger studies are needed in order to confirm our results and to compare these 
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two devices in terms of overall costs, maybe employing Harmonic ACE Plus® even in 




Table 1 Patients’ clinical characteristics: comparison between Group A (electric hook) and 








Male, n (%) 36 (53) 36 (69) 0.07 
Age, median (IQR)  year 69 (62-75) 72 (64-76) 0.47 
BMI, median (IQR)  kg/m2 25 (22-28) 26 (23-28) 0.78 
Current/former smoker, n (%) 51 (75) 39 (75) 1.00 
FEV1, median (IQR)  % 99 (88-110) 106 (89-119) 0.22 
DLCO, median (IQR) 83 (62-92)a 85 (77-96)b 0.07 
COPD, n (%) 11 (16) 11 (21) 0.48 
Previous myocardial infarction, n (%) 8 (12) 8 (15) 0.56 
Diabetes mellitus, n (%) 9 (13) 9 (17) 0.54 
Previous malignancy, n (%) 27 (40) 15 (29) 0.22 
BMI=body mass index; COPD=chronic obstructive pulmonary disease; DLCO=lung diffusing 
capacity for carbon monoxide; FEV1=forced expiratory volume in 1 second; IQR=interquartile 
range; a=data not available in 9 patients; b=data not available in 6 patients. 
  
 31 
Table 2 Patients’ pathological characteristics: comparison between Group A (electric hook) 








Tumor size, median (IQR)  cm  1.8 (1.5-2.9) 1.9 (1.5-3.0) 0.81 
Tumor histology, n (%)   0.79 
   Adenocarcinoma 45 (66) 37 (71)  
   Squamous cell carcinoma 11 (16) 8 (15)  
   Neuroendocrine tumor 10 (15) 7 (13)  
   Other histology 2 (3) 0  
Lower lobe tumor location, n (%)  17 (25) 28 (53) <0.01 
Dissected lymph nodes, median (IQR) n 8 (6-10) 8 (5-12) 0.44 
Pathological stage, n (%)   0.46 
   I 52 (76) 44 (85)  
   II 12 (18) 5 (10)  




Table 3 Risk factors for increased (>315 ml) pleural effusion volume during the first 48 hours 
after VATS lobectomy and lymphadenectomy in 120 patients: univariable and multivariable 




Univariable analysis Multivariable analysis 
HR (95%CI) p HR (95%CI) p 
Age (continuous) 1.00 (0.96-1.03) 0.83 - - 
Gender (male vs female) 2.02 (0.96-4.24) 0.06 1.36 (0.58-3.17) 0.48 
BMI (continuous) 1.00 (1.00-1.00) 0.21 - - 
FEV1 (continuous) 0.99 (0.98-1.01) 0.54 - - 
DLCO (continuous) 1.00 (0.98-1.03) 0.74 - - 
Cardiac comorbidity (none vs yes) 2.23 (0.96-5.19) 0.06 2.86 (1.09-7.45) 0.03 
Pleural adhesiolysis (none vs yes) 1.16 (0.54-2.48) 0.70 - - 
Site of resection (upper/middle vs lower) 4.13 (1.86-9.16) <0.01 3.28 (1.37-7.83) <0.01 
N° of resected lymph nodes (continuous) 1.04 (0.96-1.12) 0.39 - - 
Energy device (ultrasonic vs monopolar) 0.33 (0.15-0.70) <0.01 0.59 (0.25-1.42) 0.24 
Surgery duration (<195 vs >195 minutes) 3.73 (1.75-7.94) <0.01 2.93 (1.22-7.04) 0.02 
Postoperative air-leak>5 days (none vs yes) 1.36 (0.56-3.29) 0.50 - - 
BMI=body mass index; DLCO=lung diffusing capacity for carbon monoxide; FEV1=forced 
expiratory volume in 1 second. 
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Table 4 Risk factors for prolonged (>5 days) postoperative chest tube duration after VATS 
lobectomy and lymphadenectomy in 120 patients: univariable and multivariable analyses by 




Univariable analysis Multivariable analysis 
HR (95%CI) p HR (95%CI) p 
Age (continuous) 1.05 (1.00-1.09) 0.04 1.04 (0.99-1.10) 0.13 
Gender (male vs female) 2.41 (1.10-5.29) 0.03 1.63 (0.60-4.39) 0.34 
BMI (continuous) 1.00 (1.00-1.00) 0.35 - - 
FEV1 (continuous) 0.99 (0.97-1.01) 0.39 - - 
DLCO (continuous) 0.99 (0.97-1.01) 0.38 - - 
Cardiac comorbidity (none vs yes) 0.67 (0.28-1.59) 0.36 - - 
Pleural adhesiolysis (none vs yes) 2.69 (1.23-5.88) 0.01 2.14 (0.80-5.73) 0.13 
Site of resection (upper/middle vs lower) 0.91 (0.43-1.95) 0.81 - - 
N° of resected lymph nodes (continuous) 1.02 (0.94-1.11) 0.60 - - 
Energy device (ultrasonic vs monopolar) 0.79 (0.38-1.66) 0.54 1.32 (0.49-3.52) 0.59 
Surgery duration (<195 vs >195 minutes) 1.46 (0.70-3.04) 0.32 - - 
Postoperative air-leak >5 days (none vs yes) 75.1 (9.62-586) <0.01 63.5 (7.80-517)) <0.01 
BMI=body mass index; DLCO=lung diffusing capacity for carbon monoxide; FEV1=forced 
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8th edition of TNM Classification for lung cancer [13] 
T – Primary Tumor Classification 
TX Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in 
sputum or bronchial washings but not visualized by imaging or bronchoscopy. 
T0 No evidence of primary tumor. 
Tis Carcinoma in situ. 
T1 Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without 
bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main 
bronchus) 
    T1mi Minimally invasive adenocarcinoma. 
    T1a Tumor 1 cm or less in greatest dimension. 
    T1b Tumor more than 1 cm but not more than 2 cm in greatest dimension. 
    T1c Tumor more than 2 cm but not more than 3 cm in greatest dimension. 
T2 Tumor more than 3 cm but not more than 5 cm; or tumor with any of the following features: 
• Involves main bronchus regardless of distance to the carina, but without involving the carina 
• Invades visceral pleura 
• Associated with atelectasis or obstructive pneumonitis that extends to the hilar region, either 
involving part of the lung or the entire lung. 
    T2a Tumor more than 3 cm but not more than 4 cm in greatest dimension. 
    T2b Tumor more than 4 cm but not more than 5 cm in greatest dimension. 
T3 Tumor more than 5 cm but not more than 7 cm in greatest dimension or one that directly 
invades any of the following: chest wall (including superior sulcus tumors), phrenic nerve, 
parietal pericardium; or associated separate tumor nodule(s) in the same lobe as the primary. 
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T4 Tumors more than 7 cm or one that invades any of the following: diaphragm, mediastinum, 
heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina; 
separate tumor nodule(s) in a different ipsilateral lobe to that of the primary. 
 
N – Regional Lymph Nodes Classification 
NX Regional lymph nodes cannot be assessed. 
N0 No regional lymph node metastasis. 
N1 Metastasis in ipsilateral peri bronchial and/or ipsilateral hilar lymph nodes and 
intrapulmonary nodes, including involvement by direct extension. 
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). 
N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene 
or supraclavicular lymph node(s). 
 
M- Distant Metastasis 
M0 No distant metastasis. 
M1 Distant metastasis. 
    M1a Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial 
nodules or malignant pleural or pericardial effusion. 
    M1b Single extra thoracic metastasis in a single organ (thin includes involvement of a single 
distant, non-regional node). 
    M1c Multiple extra thoracic metastases in one or several organs. 
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Stage grouping for the 8th edition of TNM Classification for lung cancer [13] 
 
Stage T N M 
Occult carcinoma TX N0 M0 
0 Tis N0 M0 
IA1 T1a (mi) N0 M0 
 T1a N0 M0 
IA2 T1b N0 M0 
IA3 T1c N0 M0 
IB T2a N0 M0 
IIA T2b N0 M0 
IIB T1a N1 M0 
 T1b N1 M0 
 T1c N1 M0 
 T2a N1 M0 
 T2b N1 M0 
 T3 N0 M0 
IIIA T1a N2 M0 
 T1b N0 M0 
 T1c N2 M0 
 T2a N2 M0 
 T2b N2 M0 
 T3 N1 M0 
 T4 N0 M0 
 T4 N1 M0 
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IIIB T1a N3 M0 
 T1b N3 M0 
 T1c N3 M0 
 T2a N3 M0 
 T2b N3 M0 
 T3 N2 M0 
 T4 N2 M0 
IIIC T3 N3 M0 
 T4 N3 M0 
IVA Any T Any N M1a 
 Any T Any N M1b 
IVB Any T Any N M1c 
 
